Impacts of pharmacist's medication care in diabetic

Impacts of pharmacist's medication care in type 2 diabetic to prevent cardiovascular disease

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150706023084N20

Enrollment

Registered

2024-06-05

Start date

2022-09-23

Completion date

Unknown

Last updated

2024-06-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes. Type 2 diabetes mellitus with other specified complications

Interventions

Intervention 1: Intervention group:30 type 2 diabetes patients who were included in the study were initially checked for blood sugar, blood fat, blood pressure and the risk of cardiovascular disease,

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes with age limit of 18-70 years

Exclusion criteria

Exclusion criteria: Pregnant and lactating patients

Design outcomes

Primary

Measure	Time frame
Fasting blood sugar. Timepoint: the beginning of the study and 3 months later. Method of measurement: Laboratory blood sample.;Cardiovascular disease risk (Framingham Risk Score). Timepoint: The beginning of the study and 3 months later. Method of measurement: Software (Framingham Risk Score).;Hemoglobin A1c. Timepoint: The beginning of the study and 3 months later. Method of measurement: Laboratory blood sample.;Cholesterol. Timepoint: The beginning of the study and 3 months later. Method of measurement: Laboratory blood sample.;Triglycerides. Timepoint: The beginning of the study and 3 months later. Method of measurement: Laboratory blood sample.;Blood pressure. Timepoint: The beginning of the study and 3 months later. Method of measurement: Mercury sphygmomanometer.	—

Measure

Time frame

Fasting blood sugar. Timepoint: the beginning of the study and 3 months later. Method of measurement: Laboratory blood sample.;Cardiovascular disease risk (Framingham Risk Score). Timepoint: The beginning of the study and 3 months later. Method of measurement: Software (Framingham Risk Score).;Hemoglobin A1c. Timepoint: The beginning of the study and 3 months later. Method of measurement: Laboratory blood sample.;Cholesterol. Timepoint: The beginning of the study and 3 months later. Method of measurement: Laboratory blood sample.;Triglycerides. Timepoint: The beginning of the study and 3 months later. Method of measurement: Laboratory blood sample.;Blood pressure. Timepoint: The beginning of the study and 3 months later. Method of measurement: Mercury sphygmomanometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam shiehmorteza

Islamic Azad University

mshi1973@yahoo.com+98 21 2660 2642

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026